AHA today urged the Centers for Medicare & Medicaid Services to provide flexibility regarding the agency’s new COVID-19 test documentation requirement for the diagnostic-related group add-on payment.

“This new requirement will put substantial administrative burden on hospitals at a time when they are focusing their efforts and resources on critical patient care,” the association wrote. “Thus, we urge CMS to allow provider documentation to suffice if the test result is unavailable.”

The Coronavirus Aid, Relief, and Economic Security Act provided a 20% add-on to the inpatient prospective payment system DRG rate for patients diagnosed with COVID-19 during the public health emergency. CMS recently added a requirement to have a positive COVID-19 laboratory test documented in the patient’s medical record in order for the claim to be eligible. The new requirement would be applied to admissions on or after Sept. 1, 2020.

“We have heard from our hospital members that acquiring test results from other health care providers, local testing centers and other third party entities can be a burdensome process, sometimes resulting in long delays or unobtainable results,” the letter notes. “In order to receive the add-on payment, hospitals would have to dedicate considerable time and effort to obtain a patient’s third party result to manually add into the medical record, and in some cases would ultimately have to re-test the patient.”

Related News Articles

Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The AHA Sept. 29 asked the Trump administration to provide exemptions for health care personnel from the proclamation issued Sept. 19 announcing changes to the…
Headline
The Office of Science and Technology Policy issued a request for information Sept. 26 seeking feedback on federal regulations that hinder AI development,…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The House Appropriations Committee today released bill text for a continuing resolution to fund the government through Nov. 21. The bill also extends key…